drugset / Trial / NCT06083870
An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of Oba01 for injection in patients with DR5 positive LA/mNSCLC.
Timeline
- Start
- 2023-12-13
- Primary completion
- 2025-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oba01 | Unknown | 0.15 mg/kg | Intravenous |
| Subject | Oba01 | Unknown | 0.5 mg/kg | Intravenous |
| Subject | Oba01 | Unknown | 0.75 mg/kg | Intravenous |
| Subject | Oba01 | Unknown | 1 mg/kg | Intravenous |